Targeting metastatic cancer from the inside: A new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ

International Journal of Oncology

Volumn 33, Issue 4, 2008, Pages 665-675

  Gordon, Erlinda M ^a,b   Levy, John P ^a   Reed, Rebecca A ^a   Petchpud, W Nina ^a   Liu, Liqiong ^a,b   Wendler, Carlan B ^b   Hall, Frederick L ^a  

^a Epeius Biotechnologies Corporation   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cytokines; Gene therapy; Gene transfer; Granulocyte macrophage colony stimulating factor; Nanomedicine; Pathotropic nanoparticles

Indexed keywords

ANTINEOPLASTIC AGENT; CD40 ANTIGEN; CD86 ANTIGEN; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOSTIMULATING AGENT; RETROVIRUS VECTOR; REXIMMUNE C; REXIN G; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CANCER CELL; CANCER IMMUNIZATION; CARCINOMA IN SITU; CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG TARGETING; FEASIBILITY STUDY; GENE EXPRESSION; GENETIC CODE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; IN VITRO GENE TRANSFER; IN VIVO GENE TRANSFER; METASTASIS; MONONUCLEAR CELL; MOUSE; NANOENCAPSULATION; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PARACRINE SIGNALING; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; MICE; NEOPLASM METASTASIS; NEOPLASMS; NIH 3T3 CELLS; TRANSGENES;

EID: 54049112241     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo_00000052     Document Type: Article

References (47)

1. Warren TL and Weiner GJ: Uses of granulocyte-macrophage colony- stimulating factor in vaccine development. Curr Opin Hematol 7: 168-173, 2000.
2. Kim JJ, Yang JS, Lee DJ, Nottingham LK, Morrison L, Tsai A, Oh J, Dang K, Dentchev T, Agadjanyan MG, Sin JL, Chalian AA and Weiner DB: Macrophage colony-stimulating factor can modulate immune responses and attract dendritic cells in vivo. Hum Gene Ther 11: 305-321, 2000.
3. Jaffee EM: Immunotherapy for cancer. Ann NY Acad Sci 886: 67-72, 1999.
4. Drannoff G: GM-CSF-based cancer vaccines. Immunol Rev 188: 147-154, 2002.
5. Eager R and Nemunaitis J: GM-CSF gene-transduced tumor vaccines. Mol Ther 12: 18-27, 2005.
6. Suh KW, Piantadosi S, Yazdi HA, Pardoll DM, Brem H and Choti MA: Treatment of liver metastases from colon carcinoma with autologous tumor vaccine expressing granulocyte-macrophage colony-stimulating factor. J Surg Oncol 72: 218-224, 1999.
7. Soiffer R, Hodi FS, Haluska F, Jung K, Gillessen S, Singer S, Tanabe K, Duda R, Mentzer S, Jaklitsch M, Bueno R, Clift S, Hardy S, Neuberg D, Mulligan R, Webb I, Mihm M and Dranoff G: Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 21: 3343-3350, 2003.
8. Mellstedt H, Fagerberg J, Frodin JE, Henriksson L, Hjelm-Skoog AL, Liljefors M, Ragnhammar P and Osterborg A: Augmentation of the immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factors. Curr Opin Hematol 6: 169-175, 1999.
9. Nagai E, Ogawa T, Ikubo A and Suzuki T: Irradiated tumor cells adenovirally engineered to secrete granulocyte/ macrophage-colony-stimulating factor establish antitumor immunity and eliminate pre-existing tumors in syngeneic mice. Cancer Immunol Immunother 47: 72-80, 1998.
10. Fong TC, Sauter SL, Ibanez CE, Sheridan PL and Jolly DJ: The use and development of retroviral vectors to deliver cytokine genes for cancer therapy. Crit Rev Ther Drug Carrier Syst 17: 1-60, 2000.
11. Borrello I, Sotomayor EM, Cooke S and Levitsky HI: A universal granulocyte macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines. Hum Gene Ther 10: 1983-1991, 1999.
12. Tai K, Chen D and Hwang L: Curative potential of GM-CSF-secreting tumor cell vaccines on established orthotopic liver tumors: mechanisms for the superior antitumor activity of liver tumor cell vaccines. J Biomed Sci 11: 228-238, 2004.
13. Kurane S, Arca MT, Aruga A, Krinock RA, Krauss JC and Chang AE: Cytokines as an adjuvant to tumor vaccines: efficacy of local methods of delivery. Ann Surg Oncol 4: 579-585, 1997.
14. Dranoff G: Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 4: 11-22, 2004.
15. Zhang Y and Chatterjee DK: Liposomes, dendrimers and other polymeric nanoparticles for targeted delivery of anticancer agents - a comparative study. In: Nanomaterials for Cancer Therapy. Kumar C (ed.) Wiley-VCH Verlag, pp338-370, 2006.
16. Waehler R, Russell SJ and Curiel DT: Engineering targeted viral vectors for gene therapy. Nat Rev Genet 8: 573-587, 2007.
17. Hitt MM and Gauldie J: Gene vectors for cytokine expression in vivo. Curr Pharm Des 6: 613-632, 2000.
18. Young LS, Searle PF, Onion D and Mautner V: Viral gene therapy strategies: from basic science to clinical application. J Pathol 208: 299-318, 2006.
19. Pensiero MN, Wysocki CA, Nader K and Kikuchi GE: Development of amphotropic retrovirus vectors resistant to inactivation by human serum. Hum Gene Ther 8: 1095-1101, 1996.
20. De Polo NJ, Harkleroad CE, Bodner M, Watt AT, Anderson CG, Greengard JS, Murthy KK, Dubensky TW Jr and Jolly DJ: The resistance of retroviral vectors produced from human cells to serum inactivation in vivo and in vitro is primate species dependent. J Virol 73: 6708-6714, 1999.
21. Miller DG, Adam MA and Miller AD: Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 101: 4239-4242, 1990.
22. Gordon EM and Hall F: Nanotechnology blooms, at last (Review). Oncol Rep 13: 1003-1007, 2005.
23. Adamina M, Daetwiler S, Rosenthal R and Zajac P: Clinical application of recombinant virus-based cancer immunotherapy. Expert Opin Biol Ther 5: 1211-1224, 2005.
24. Verma IM and Weitzman MD: Gene therapy: twenty-first century medicine. Annu Rev Biochem 74: 711-738, 2005.
25. Yu SS, Han E, Hong Y, Lee JT, Kim S and Kim S: Construction of a retroviral vector production system with the minimum possibility of a homologous recombination. Gene Ther 10: 706-711, 2003.
26. Zhao Y, Zhu Y, Lee S, Li L, Chang E, Soong N-W, Douer D and Anderson WF: Identification of the block in targeted retroviral-mediated gene transfer. Proc Natl Acad Sci USA 96: 4005-4019, 1999.
27. Cosset FL, Morling FJ, Takeuchi U, Weiss RA, Collins MK and Russell SJ: Retroviral retargeting by envelopes expressing an N-terminal binding domain. J Virol 69: 6314-6322, 1995.
28. Peng K and Russell SJ: Viral vector targeting. Curr Opin Biotechnol 10: 454-457, 1999.
29. Hall FL, Gordon EM, Wu L, Zhu NL, Skotzko MJ, Starnes VA and Anderson WF: Targeting retroviral vectors to vascular lesions by genetic engineering of the MoMuLV gp70 envelope protein. Hum Gene Ther 8: 2183-2192, 1997.
30. Hall FL, Liu L, Zhu NL, Stapfer M, Anderson WF, Beart RW and Gordon EM: Molecular engineering of matrix-targeted retroviral vectors incorporating a surveillance function inherent in von Willebrand factor. Hum Gene Ther 11: 983-993, 2000.
31. Masood R, Gordon EM, Whitley MD, Wu BW, Cannon P, Evans L, Anderson WF, Gill P and Hall FL: Retroviral vectors bearing IgG-binding motifs for antibody-mediated targeting of vascular endothelial growth factor receptors. Int J Mol Med 8: 335-343, 2001.
32. Gordon EM, Liu PX, Chen ZH, Liu L, Whitley MD, Gee C, Groshen S, Hinton DR, Beart RW and Hall FL: Inhibition of metastatic tumor growth in nude mice by portal vein infusions of matrix-targeted retroviral vectors bearing a cytocidal cyclin G1 construct. Cancer Res 60: 3343-3347, 2000.
33. Gordon EM, Liu PX, Chen ZH, Liu L, Whitley M, Liu L, Wei D, Groshen S, Hinton DR, Anderson WF, Beart RW and Hall FL: Systemic administration of a matrix-targeted retroviral vector is efficacious for cancer gene therapy in mice. Hum Gene Ther 12: 193-204, 2000.
34. Gordon EM, Comelio GH, Lorenzo CC, Levy JP, Reed RA, Liu L and Hall FL: First clinical experience using a 'pathotropic' injectable retroviral vector (Rexin-G) as intervention for Stage IV pancreatic cancer. Int J Clin Oncol 24: 177-185, 2004.
35. Gordon EM, Lopez FF, Cornelio GH, Lorenzo CC III, Levy JP, Reed RA, Liu L, Bruckner HW and Hall FL: Pathotropic nanoparticles for cancer gene therapy. Rexin-G: three-year clinical experience. Int J Oncol 29: 1053-1064, 2006.
36. Gordon EM, Chan MT, Geraldino N, Lopez FF, Comelio GH, Lorenzo CC III, Levy JP, Reed RA, Liu L and Hall FL: Le morte du tumour: histological features of tumor destruction in chemo-resistant cancers following intravenous infusions of pathotropic nanoparticles bearing therapeutic genes. Int J Oncol 30: 1297-1307, 2007.
37. Soneoka Y, Cannon PM, Ramsdale EE, Griffiths JC, Romano G, Kingsman SM and Kingsman AJ: A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res 23: 628-633, 1995.
38. Skotzko MJ, Wu LT, Anderson WF, Gordon EM and Hall FL: Retroviral vector-mediated gene transfer of antisense cyclin G1 (CYCG1) inhibits proliferation of human osteogenic sarcoma cells. Cancer Res 55: 5493-5498, 1995.
39. Fogolin MB, Eberhardt MO, Kratje R and Etcheverrigaray M: Choice of the adequate quantification method for recombinant human GM-CSF produced in different host systems, J Biotech 5: 243-250, 2002.
40. Miller AD and Rosman GJ: Improved retroviral vectors for gene transfer and expression. Biotechniques 7: 984-986, 1989.
41. Kim SH, Yu SS, Park JS, Robbins PD, An CS and Kim S: Construction of retroviral vectors with improved safety, gene expression, and versatility. J Virol 72: 994-1004, 1998.
42. Yu SS, Kim JM and Kim S: High efficiency retroviral vectors that contain no viral coding sequences. Gene Ther 7: 797-804, 2000.
43. Lenz HJ, Anderson WF, Hall FL and Gordon EM: Clinical protocol: tumor site specific phase I evaluation of safety and efficacy of hepatic arterial infusion of a matrix-targeted retroviral vector bearing a dominant negative cyclin G1 construct as intervention for colorectal carcinoma metastatic to liver. Hum Gene Ther 10: 1515-1537, 2002.
44. Cornelio GH, Lorenzo CC, Lopez FF, Hall FL and Gordon EM: Phase I study of sequential targeted gene delivery: intravenous infusions of Rexin-G followed by Reximmune-C induce tumor necrosis and recruitment of tumor infiltrating lymphocytes in cancerous lesions. J Clin Oncol 26: 3077, 2008.
45. Ullenhag GJ, Frodin JE, Jeddi-Tehrani M, Strigard K, Eriksson E, Samanci A, Choudhury A, Nilsson B, Rossman ED, Mosolits S and Mellstedt H: Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte-macrophage colony-stimulating factor. Clin Cancer Res 15: 3273-3281, 2004.
46. Waller EK: The role of sargramostim (rhGM-CSF) as immunotherapy. Oncologist 12: 22-26, 2007.
47. Parmiani G, Castelli C, Pilla L, Santinami M, Colombo MP and Rivoltini L: Opposite immune function of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol 18: 226-232, 2007.